Furosemide in indomethacin-treated infants systematic review and meta-analysis

Luc P. Brion, Deborah E. Campbell

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This study was designed to assess: (1) whether furosemide modifies the incidence of failure to close a symptomatic patent ductus arteriosus (PDA) in response to indomethacin in premature infants, (2) whether furosemide decreases renal and hydromineral side effects of indomethacin, and (3) whether the effects of furosemide on renal function depend on initial extracellular volume [assessed by blood urea nitrogen (BUN)/creatinine ratio]. We did a systematic review and meta-analysis of all published controlled trials assessing either ductal closure or renal function after randomized allocation to treatment with indomethacin and furosemide versus indomethacin alone. All of the three studies meeting entry criteria were small and had methodological limitations. The number of patients was too small to rule out a 10% risk increase in failure of ductal closure. After the first dose of indomethacin, patients receiving furosemide had higher urine output, fractional excretion of sodium, and osmolar clearance than controls. Among patients with initial BUN/creatinine ratio < 20, those on furosemide had a higher glomerular filtration rate (GFR) than controls. Among patients with initial BUN/creatinine of 20-30, those on furosemide had a lower GFR than controls. Thus, dehydration appears to be a contraindication for furosemide administration in premature infants treated with indomethacin for symptomatic PDA. The risk-benefit ratio of administering furosemide in well-hydrated patients treated with indomethacin for symptomatic PDA could only be assessed by a large randomized clinical trial.

Original languageEnglish (US)
Pages (from-to)212-218
Number of pages7
JournalPediatric Nephrology
Volume13
Issue number3
DOIs
StatePublished - Apr 1999

Fingerprint

Furosemide
Indomethacin
Meta-Analysis
Patent Ductus Arteriosus
Blood Urea Nitrogen
Creatinine
Glomerular Filtration Rate
Kidney
Premature Infants
Dehydration
Randomized Controlled Trials
Sodium
Odds Ratio
Urine
Incidence

Keywords

  • Furosemide
  • Indomethacin
  • Infant, newborn
  • Meta-analysis
  • Patent ductus arteriosus
  • Renal function

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Furosemide in indomethacin-treated infants systematic review and meta-analysis. / Brion, Luc P.; Campbell, Deborah E.

In: Pediatric Nephrology, Vol. 13, No. 3, 04.1999, p. 212-218.

Research output: Contribution to journalArticle

@article{f9a7e401f08444e1b35097570ce0071a,
title = "Furosemide in indomethacin-treated infants systematic review and meta-analysis",
abstract = "This study was designed to assess: (1) whether furosemide modifies the incidence of failure to close a symptomatic patent ductus arteriosus (PDA) in response to indomethacin in premature infants, (2) whether furosemide decreases renal and hydromineral side effects of indomethacin, and (3) whether the effects of furosemide on renal function depend on initial extracellular volume [assessed by blood urea nitrogen (BUN)/creatinine ratio]. We did a systematic review and meta-analysis of all published controlled trials assessing either ductal closure or renal function after randomized allocation to treatment with indomethacin and furosemide versus indomethacin alone. All of the three studies meeting entry criteria were small and had methodological limitations. The number of patients was too small to rule out a 10{\%} risk increase in failure of ductal closure. After the first dose of indomethacin, patients receiving furosemide had higher urine output, fractional excretion of sodium, and osmolar clearance than controls. Among patients with initial BUN/creatinine ratio < 20, those on furosemide had a higher glomerular filtration rate (GFR) than controls. Among patients with initial BUN/creatinine of 20-30, those on furosemide had a lower GFR than controls. Thus, dehydration appears to be a contraindication for furosemide administration in premature infants treated with indomethacin for symptomatic PDA. The risk-benefit ratio of administering furosemide in well-hydrated patients treated with indomethacin for symptomatic PDA could only be assessed by a large randomized clinical trial.",
keywords = "Furosemide, Indomethacin, Infant, newborn, Meta-analysis, Patent ductus arteriosus, Renal function",
author = "Brion, {Luc P.} and Campbell, {Deborah E.}",
year = "1999",
month = "4",
doi = "10.1007/s004670050595",
language = "English (US)",
volume = "13",
pages = "212--218",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Furosemide in indomethacin-treated infants systematic review and meta-analysis

AU - Brion, Luc P.

AU - Campbell, Deborah E.

PY - 1999/4

Y1 - 1999/4

N2 - This study was designed to assess: (1) whether furosemide modifies the incidence of failure to close a symptomatic patent ductus arteriosus (PDA) in response to indomethacin in premature infants, (2) whether furosemide decreases renal and hydromineral side effects of indomethacin, and (3) whether the effects of furosemide on renal function depend on initial extracellular volume [assessed by blood urea nitrogen (BUN)/creatinine ratio]. We did a systematic review and meta-analysis of all published controlled trials assessing either ductal closure or renal function after randomized allocation to treatment with indomethacin and furosemide versus indomethacin alone. All of the three studies meeting entry criteria were small and had methodological limitations. The number of patients was too small to rule out a 10% risk increase in failure of ductal closure. After the first dose of indomethacin, patients receiving furosemide had higher urine output, fractional excretion of sodium, and osmolar clearance than controls. Among patients with initial BUN/creatinine ratio < 20, those on furosemide had a higher glomerular filtration rate (GFR) than controls. Among patients with initial BUN/creatinine of 20-30, those on furosemide had a lower GFR than controls. Thus, dehydration appears to be a contraindication for furosemide administration in premature infants treated with indomethacin for symptomatic PDA. The risk-benefit ratio of administering furosemide in well-hydrated patients treated with indomethacin for symptomatic PDA could only be assessed by a large randomized clinical trial.

AB - This study was designed to assess: (1) whether furosemide modifies the incidence of failure to close a symptomatic patent ductus arteriosus (PDA) in response to indomethacin in premature infants, (2) whether furosemide decreases renal and hydromineral side effects of indomethacin, and (3) whether the effects of furosemide on renal function depend on initial extracellular volume [assessed by blood urea nitrogen (BUN)/creatinine ratio]. We did a systematic review and meta-analysis of all published controlled trials assessing either ductal closure or renal function after randomized allocation to treatment with indomethacin and furosemide versus indomethacin alone. All of the three studies meeting entry criteria were small and had methodological limitations. The number of patients was too small to rule out a 10% risk increase in failure of ductal closure. After the first dose of indomethacin, patients receiving furosemide had higher urine output, fractional excretion of sodium, and osmolar clearance than controls. Among patients with initial BUN/creatinine ratio < 20, those on furosemide had a higher glomerular filtration rate (GFR) than controls. Among patients with initial BUN/creatinine of 20-30, those on furosemide had a lower GFR than controls. Thus, dehydration appears to be a contraindication for furosemide administration in premature infants treated with indomethacin for symptomatic PDA. The risk-benefit ratio of administering furosemide in well-hydrated patients treated with indomethacin for symptomatic PDA could only be assessed by a large randomized clinical trial.

KW - Furosemide

KW - Indomethacin

KW - Infant, newborn

KW - Meta-analysis

KW - Patent ductus arteriosus

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=0032934568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032934568&partnerID=8YFLogxK

U2 - 10.1007/s004670050595

DO - 10.1007/s004670050595

M3 - Article

C2 - 10353408

AN - SCOPUS:0032934568

VL - 13

SP - 212

EP - 218

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -